TrialCannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Trial details
- Registry ID
- NCT04615949
- Phase
- Phase 2, Phase 3
CRDL
Cardiol Therapeutics Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949 | CRDL | Phase 2, Phase 3 | Terminated | 2022-11-30Actual |
| Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisNCT05180240 | CRDL | Phase 2 | Completed | 2025-01-31Actual |
| Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)NCT05494788 | CRDL | Phase 2 | Completed | 2024-06-15Actual |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)NCT06708299 | CRDL | Phase 3 | Recruiting | 2026-09-21Estimated |
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
Trial details
- Registry ID
- NCT05180240
- Phase
- Phase 2
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Trial details
- Registry ID
- NCT05494788
- Phase
- Phase 2
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
Trial details
- Registry ID
- NCT06708299
- Phase
- Phase 3
Latest recorded trial changes
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299 · Cardiol Therapeutics Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Recurrence of pericarditis
+ After
Measure: time to pericarditis recurrence
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
NCT05180240 · Cardiol Therapeutics Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: extracellular volume (ECV)
Measure: Global longitudinal Strain (GLS)
+ After
Measure: Extracellular Volume (ECV) Measure: Global Longitudinal Strain (GLS)
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
NCT04615949 · Cardiol Therapeutics Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: All-cause Mortality
+ After
Measure: Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications